1. Home
  2. VRTX vs DE Comparison

VRTX vs DE Comparison

Compare VRTX & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$464.65

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo Deere & Company

DE

Deere & Company

HOLD

Current Price

$526.56

Market Cap

132.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
DE
Founded
1989
1837
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Industrial Machinery/Components
Sector
Technology
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
132.0B
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
VRTX
DE
Price
$464.65
$526.56
Analyst Decision
Buy
Buy
Analyst Count
27
18
Target Price
$501.42
$524.11
AVG Volume (30 Days)
1.4M
1.3M
Earning Date
02-12-2026
02-12-2026
Dividend Yield
N/A
1.27%
EPS Growth
N/A
N/A
EPS
14.22
18.50
Revenue
$11,723,300,000.00
$45,628,000,000.00
Revenue This Year
$10.93
N/A
Revenue Next Year
$8.44
$9.20
P/E Ratio
$31.08
$27.50
Revenue Growth
10.33
N/A
52 Week Low
$362.50
$404.42
52 Week High
$519.68
$533.78

Technical Indicators

Market Signals
Indicator
VRTX
DE
Relative Strength Index (RSI) 55.63 69.87
Support Level $429.00 $507.89
Resistance Level $487.52 $519.18
Average True Range (ATR) 12.79 13.88
MACD -2.15 4.60
Stochastic Oscillator 57.70 99.67

Price Performance

Historical Comparison
VRTX
DE

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About DE Deere & Company

Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production & precision agriculture (PPA), small agriculture & turf (SAT), construction & forestry (CF), and financial services (FS), its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere financial provides retail financing for machinery to its customers and wholesale financing for dealers.

Share on Social Networks: